This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Don't Read Too Much Into the Downers of the Dow

By: Nicole Urken | 01/21/14 - 10:34 PM EST

NEW YORK (TheStreet) -Today's market ended with the Dow Jones Industrial Average down 44 points while the S&P was in fact up 0.28%. Why the divergence? Key Dow components reported quarters that were seen as disappointing, but ultimately, as I highlight below, these names are still well positioned and we still see an underlying healthy market. 

The downers of the Dow?

Verizon (VZ): While the company reported a solid quarter (ie solid wireless results and improving wireline margins), Verizon didn't give fulsome 2014 guidance--largely due to pending Vodafone deal. Yes, there is more spending coming for the company: Verizon guided for full-year 2014 capex of $16.5 billion to $17.0 billion, about 2% higher than consensus expectations (beneficiaries include names like Ciena (CIEN) and Juniper (JNPR) along with the tower companies like SBA Communications (SBAC) and American Tower (AMT)). And yes, the company will be issuing 1.2 billion new shares related to the Vodafone deal, expected to close in a month. But that will be temporary pressure and the company still has a solid dividend with growth.

Travelers (TRV): The insurance giant reported a fourth quarter beat, but the stock sold off as investors worried about pricing slowing, a question-mark that has been plaguing the full property & casualty (P&C) group. A still well-positioned name in the group is American International Group (AIG), which remains a turnaround name driven by P&C driven operating recovery.

Johnson & Johnson (JNJ): The quarter was solid and 2014 guidance was conservative and achievable. This is a great name in the pharma group because it is defensive but also has embraced more growth of late with pharma product launches (recent launches include Zytiga and Xarelto) with more to come (Imbruvica, Invokana), consumer products issues in the rearview, and improving utilization trends in medical devices. That 3% dividend yield is pretty compelling as well.

The bottom line: All three of the supposed disappointments in the Dow today remain well positioned. And we still saw underlying market strength in the broader averages. Still early in earnings season, we need to see more from companies before we jump to any conclusions.

Of course, one Dow component that reported after the bell remains a troubled spot: International Business Machines Corp (IBM). The financial engineering to get to the $20 EPS target in 2015 still shows no signs of real growth.. and this operational miss is keeping investors at bay.

--Written by Nicole Urken in New York.

>Contact by Email.

Other Posts In Nicole's Stocks and the City:

Is the robust IPO market affecting the broader indices?

04/10/14 - 03:53 PM EDT

The Momentum Tell and the Yellen Timeline

04/10/14 - 02:47 PM EDT

Under Armour is cheap! (yes, I said cheap)

03/27/14 - 06:26 PM EDT

FedEx Corp is a Buy

03/19/14 - 01:58 PM EDT

Tech in Transition: The Winners

03/19/14 - 11:01 AM EDT

To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs